Susan Rienow becomes President of the ABPI

Susan Rienow, UK Managing Director and Country President of Pfizer, is taking up her role as President of the Association of the British Pharmaceutical Industry.

Putting patients at the heart of everything we do and ensuring that the UK becomes a global life sciences leader are the twin goals that drive my priorities as President. Susan Rienow, ABPI President

She will lead on overseeing the ABPI, the ABPI Board, and the ABPI’s Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA).

Susan takes up the Presidency as negotiations begin for a new Voluntary Scheme for branded medicines pricing between the government, NHS England and the ABPI.

All parties are looking to secure a new agreement that will help improve patient outcomes, support a healthier population and a financially sustainable NHS, while also supporting economic growth for the UK.

Susan’s presidency will have three broad priorities:
• Agreeing a sustainable successor to the Voluntary Scheme, so that we return the UK to internationally competitive payment rates and deliver a sustainable approach to medicines provision

• Securing better access to innovative medicines and vaccines for patients on the NHS, which will critical to overcoming the backlog and improving the NHS’s resilience to future health challenges

• Working in partnership to ensure that life sciences can be a key enabler of future economic growth and prosperity for the UK

Susan Rienow, President of the ABPI said:

“Innovative medicines can help transform people’s lives, and getting better access to them for people on the NHS can also help the NHS deal with some of the challenges it faces.”

"The life sciences sector is a growth engine for the economy, and ensuring it thrives can help deliver health, wealth and productivity for the whole of the UK.”

Welcoming Susan as President, ABPI Chief Executive Richard Torbett said:

“Having Susan’s experience and energy behind us will help us drive industry’s priorities forward and forge new relationships in our sector, the NHS and Government. I look forward to working with her as President.”



Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.